Search results
Results from the WOW.Com Content Network
Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. [5] LAG3, which was discovered in 1990 [6] and was designated CD223 (cluster of differentiation 223) after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, [7] is a cell surface molecule with diverse biological effects on T cell function but overall has an immune ...
Relatlimab is a monoclonal antibody designed for the treatment of melanoma. [3] [4] It is used in combination with nivolumab to treat melanoma. [2] [5] Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor. [2] [5] It is under development by Bristol-Myers Squibb. [2] [5] It is made using Chinese hamster ovary cells. [2]
GSK2831781 is a monoclonal antibody being developed by GlaxoSmithKline (GSK) for autoimmune diseases. The antibody targets the T cell activation marker LAG-3, which is mainly expressed in inflamed tissues. In GSK's March 2015 Product development pipeline document the antibody is listed under 'Immuno-inflammation' candidates. [1]
Eftilagimod alpha ("efti" in short) is a soluble LAG-3 fusion protein that activates antigen-presenting cells.It is a 160 kDa protein consisting of the four extracellular domains of LAG-3 fused to the Fc region of an IgG1(LAG-3Ig).
Bristol-Myers Squibb is working on Lirilumab, a monoclonal antibody to KIR. LAG3: short for Lymphocyte Activation Gene-3, works to suppress an immune response by action to Tregs [40] as well as direct effects on CD8+ T cells. [41] [38] Bristol-Myers Squibb is in Phase I with an anti-LAG3 monoclonal antibody called BMS-986016. [42]
sdAb: single-domain antibody; BsAb: bispecific monoclonal antibody: 3funct: trifunctional antibody; BiTE: bi-specific T-cell engager; This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical ...
Also Read: Merck’s Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer. At the final pre-specified analysis, the f. On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Special pages; Help; Learn to edit; Community portal; Recent changes; Upload file